Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 14/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28394924 | 0.82 | NOTUM (0.50) | NOTUMTSHRTLR8KDM4E | |
| SCHEMBL12906161 | 0.72 | NOTUM (0.59) | NOTUMTSHRMAPTTLR8KDM4E | |
| SCHEMBL5553224 | 0.72 | — | — | |
| SCHEMBL29522058 | 0.72 | — | — | |
| SCHEMBL24920787 | 0.67 | ALDH1A1 (0.43) | NOTUMNPC1RAB9AMAPTTLR8 | |
| SCHEMBL497216 | 0.67 | — | — | |
| SCHEMBL6306433 | 0.67 | NOTUM (0.39) | NOTUMTSHRNPC1RAB9AMAPT | |
| SCHEMBL5820538 | 0.67 | NOTUM (0.43) | NOTUMTSHRNPC1RAB9A | |
| SCHEMBL24921992 | 0.66 | MAPT (0.42) | NOTUMTSHRNPC1RAB9AMAPT | |
| SCHEMBL24921789 | 0.64 | NPC1 (0.38) | NOTUMTSHRNPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 300 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7855212-B2 | Pyridinyl acetonitriles | MERCK SERONO SA (CH) | 2010-12-21 | — | — | US | claimed |
| EP-1320526-B1 | PHARMACEUTICALLY ACTIVE BENZSULFONAMIDE DERIVATIVES AS INHIBITORS OF PROTEIN JUNKINASES | MERCK SERONO SA (CH) | 2010-08-18 | — | — | EP | claimed |
| EP-1399156-A2 | ALKYLIDENE PIRAZOLIDINEDIONE DERIVATIVES AND THEIR USE FOR TREATING DIABETES AND OBESITY | Applied Research Systems ARS Holding N.V. (AN) | 2004-03-24 | — | — | EP | claimed |
| WO-2002102359-A2 | ALKYLIDENE PYRAZOLIDINEDIONE DERIVATIVES AND USE FOR TREATING DIABETES AND OBESITY | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2002-12-27 | — | — | WO | claimed |
| WO-2024074436-A1 | LACTATE ENHANCING COMPOUNDS AND USES THEREOF | GLIAPHARM SA (CH) | 2024-04-11 | — | — | WO | disclosed |
| EP-4077308-B1 | ANTI-MALARIAL AGENTS | UNIV TEXAS (US) | 2024-02-14 | — | — | EP | disclosed |
| US-20230372306-A1 | COMPOSITIONS AND METHODS FOR DELAYING THE INCIDENCE OF LABOR | XOMA (US) LLC | 2023-11-23 | — | — | US | disclosed |
| US-20230277501-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY | 2023-09-07 | — | — | US | disclosed |
| EP-4132918-A1 | NEW ANTI-MALARIAL AGENTS | University Of Kentucky Research Foundation (US) | 2023-02-15 | — | — | EP | disclosed |
| EP-3892332-A1 | NEW ANTI-MALARIAL AGENTS | University Of Kentucky Research Foundation (US) | 2021-10-13 | — | — | EP | disclosed |
| WO-2021191412-A1 | CATHEPSIN SUBSTRATES & CATHEPSIN INHIBITORS AND USES THEREOF | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2021-09-30 | — | — | WO | disclosed |
| EP-3884948-A1 | CATHEPSIN INHIBITORS AND USES THEREOF | Ecole Polytechnique Fédérale de Lausanne (EPFL) (CH) | 2021-09-29 | — | — | EP | disclosed |
| WO-2001029028-A1 | 9- (PIPERAZINYLALKYL) CARBAZOLES AS BAX-MODULATORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2001-04-26 | — | — | WO | disclosed |
| EP-1094063-A1 | 9-(Piperazinylalkyl)carbazoles as Bax-modulators | Applied Research Systems ARS Holding N.V. (AN) | 2001-04-25 | — | — | EP | disclosed |
| WO-2001023378-A1 | PHARMACEUTICALLY ACTIVE SULFONAMIDE DERIVATIVES | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2001-04-05 | — | — | WO | disclosed |
| WO-2001023379-A1 | PHARMACEUTICALLY ACTIVE SULFONYL AMINO ACID DERIVATIVES | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2001-04-05 | — | — | WO | disclosed |
| WO-2001023382-A1 | PHARMACEUTICALLY ACTIVE SULFONYL HYDRAZIDE DERIVATIVES | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2001-04-05 | — | — | WO | disclosed |
| EP-1088815-A1 | Pharmaceutically active sulfonyl amino acid derivatives | Applied Research Systems ARS Holding N.V. (AN) | 2001-04-04 | — | — | EP | disclosed |
| EP-1088821-A1 | Pharmaceutically active sulfonamide derivatives | Applied Research Systems ARS Holding N.V. (AN) | 2001-04-04 | — | — | EP | disclosed |
| EP-1088822-A1 | Pharmaceutically active sulfonyl hydrazide derivatives | Applied Research Systems ARS Holding N.V. (AN) | 2001-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372306-A1 | COMPOSITIONS AND METHODS FOR DELAYING THE INCIDENCE OF LABOR | PGF, TRPV2, TRPV3 | NOTUM 883/4885TSHR 1501/4885NPC1 2357/4885 |
| US-20230277501-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | GRIN2A, CHRNA2, SYNGR2 | NOTUM 2660/4885TSHR 4626/4885NPC1 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.